These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. The effect of pimozide on CSF norepinephrine in schizophrenia. Sternberg DE; van Kammen DP; Lake CR; Ballenger JC; Marder SR; Bunney WE Am J Psychiatry; 1981 Aug; 138(8):1045-50. PubMed ID: 7258379 [TBL] [Abstract][Full Text] [Related]
7. Relation of CSF neurotensin concentrations to symptoms and drug response of psychotic patients. Garver DL; Bissette G; Yao JK; Nemeroff CB Am J Psychiatry; 1991 Apr; 148(4):484-8. PubMed ID: 2006695 [TBL] [Abstract][Full Text] [Related]
8. Plasma norepinephrine and dopamine-beta-hydroxylase activity in schizophrenia. Castellani S; Ziegler MG; van Kammen DP; Alexander PE; Siris SG; Lake CR Arch Gen Psychiatry; 1982 Oct; 39(10):1145-9. PubMed ID: 7125844 [TBL] [Abstract][Full Text] [Related]
9. Longitudinal changes in symptoms and plasma homovanillic acid levels in chronically medicated schizophrenic patients. Suzuki E; Kanba S; Nibuya M; Adachi S; Sekiya U; Shintani F; Kinoshita N; Yagi G; Asai M Biol Psychiatry; 1994 Nov; 36(10):654-61. PubMed ID: 7880934 [TBL] [Abstract][Full Text] [Related]
10. Haloperidol response and plasma catecholamines and their metabolites. Green AI; Alam MY; Boshes RA; Waternaux C; Pappalardo KM; Fitzgibbon ME; Tsuang MT; Schildkraut JJ Schizophr Res; 1993 Jun; 10(1):33-7. PubMed ID: 8369230 [TBL] [Abstract][Full Text] [Related]
11. CSF chromogranin A-like immunoreactivity in schizophrenia. Assessment of clinical and biochemical relationships. van Kammen DP; Peters J; Yao J; Neylan T; Beuger M; Pontius E; O'Connor DT Schizophr Res; 1991 Dec; 6(1):31-9. PubMed ID: 1723893 [TBL] [Abstract][Full Text] [Related]
12. Plasma homovanillic acid differences in clinical subgroups of first episode schizophrenic patients. Baeza I; Castro-Fornieles J; Deulofeu R; de la Serna E; Goti J; Salvà J; Bernardo M Psychiatry Res; 2009 Jul; 168(2):110-8. PubMed ID: 19501918 [TBL] [Abstract][Full Text] [Related]
13. Plasma 3-methoxy-4-hydroxyphenylglycol and homovanillic acid measurements in deficit and nondeficit forms of schizophrenia. Thibaut F; Ribeyre JM; Dourmap N; Ménard JF; Dollfus S; Petit M Biol Psychiatry; 1998 Jan; 43(1):24-30. PubMed ID: 9442341 [TBL] [Abstract][Full Text] [Related]
14. Pretreatment plasma homovanillic acid in schizophrenia and schizoaffective disorder: the influence of demographic variables and the inpatient drug-free period. Sharma RP; Javaid JI; Davis JM; Janicak PG Biol Psychiatry; 1998 Sep; 44(6):488-92. PubMed ID: 9777181 [TBL] [Abstract][Full Text] [Related]
15. Noradrenergic activity and prediction of psychotic relapse following haloperidol withdrawal in schizophrenia. van Kammen DP; Agren H; Yao JK; O'Connor DT; Gurklis J; Peters JL Am J Psychiatry; 1994 Mar; 151(3):379-84. PubMed ID: 7509126 [TBL] [Abstract][Full Text] [Related]
16. Clonidine treatment of schizophrenia: can we predict treatment response? van Kammen DP; Peters JL; van Kammen WB; Rosen J; Yao JK; McAdam D; Linnoila M Psychiatry Res; 1989 Mar; 27(3):297-311. PubMed ID: 2469097 [TBL] [Abstract][Full Text] [Related]